Mediar Therapeutics has raised a $105M funding round to reverse fibrotic activity by developing its own therapies.
Novartis Venture Fund and Sofinnova Partners led the funding round.
Mediar Therapeutics is a biotechnology company that aims to use a new approach for fibrosis treatment.
- Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment, and Mass General Brigham Ventures also participated in the round.
- The company aims to use the funding to advance its clinical trial process in 2023 and 2024.
- Since its inception in 2019, the company has raised $116M.
- The company is based in Cambridge, Massachusetts.
